- November 5, 2012 | BY
Samantha Budd, project leader for AstraZeneca’s Alzheimer’s program, discusses the challenges the biopharmaceutical industry faces with this neurodegenerative disease.
- October 22, 2012 | BY
Patient-derived xenografts, otherwise referred to as animal avatars, preserve the original characteristics of a patient’s cancer and have been shown to mimic the disease more effectively than deriving tumors from cancer cell lines.
- October 16, 2012 | BY
The search for Ehrlich’s Magic Bullet took a huge leap when someone asked, “Why not antibodies?”
- October 8, 2012 | BY
Once an experimental curiosity, pharmaceutical companies are embracing the 6-month transgenic mouse carcinogenicity study as an alternative to the 2-year mouse carcinogenicity bioassay. Here’s why.
- October 1, 2012 | BY
Each year in the US, approximately 3,000 children are diagnosed with leukemia, the most common childhood cancer. This cancer of the blood makes up one-third of cancer cases in children and is the leading cause of death in children up to age 14. Acute lymphoblastic leukemia (ALL) is the most common form of leukemia in ...
- September 24, 2012 | BY
Two broad types of cancer vaccines exist: preventive cancer vaccines, which target infectious agents causing cancer development, and therapeutic vaccines, which treat an existing cancer by strengthening the body’s natural defense.
- September 21, 2012 | BY
A highly publicized event perpetuated myths of harm from the MMR vaccine.
- September 20, 2012 | BY
I’m part of the generation who vividly remembers mumps’ high fever and the itching from chicken pox.
- September 18, 2012 | BY
Most of our communities have access to effective and safe medicines as well as preventative vaccines, a far cry from seven decades ago when polio filled famlies with dread.
- September 10, 2012 | BY
We’re all familiar with the common symptoms of the flu, but what we may not know is that there are a number of complications that can result from it, particularly in young children and the elderly.